替莫唑胺联合适形调强放射治疗MGMT阳性的高级别脑胶质瘤临床疗效观察

金雯雯; 张红雁; 王业涛

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

替莫唑胺联合适形调强放射治疗MGMT阳性的高级别脑胶质瘤临床疗效观察

金雯雯 , 张红雁 , 王业涛

文章导航 > 蚌埠医学院学报 > 2013, 37 > 1: (56-58)

引用本文:

Citation:

替莫唑胺联合适形调强放射治疗MGMT阳性的高级别脑胶质瘤临床疗效观察

1.
1. 安徽省立医院肿瘤放疗科;
2.
2. 安徽省立医院消化内科, 安徽合肥 230001

作者简介: 金雯雯(1983-)，女，住院医师．

通讯作者: 张红雁;

基金项目:

The clinical observation of temozolomide combined with intensity-modulated radiotherapy in the treatment of malignant glioma with positive MGMT

1.
1. Department of Radiotherapy;
2.
2. Department of Digestion, Anhui Provincial Hospital, Hefei Anhui 230001, China

Corresponding author: ZHANG Hong-yan

摘要: 目的：探讨6-氧-甲基鸟嘌呤DNA甲基转移酶(MGMT)阳性表达的患者应用替莫唑胺联合适形调强放疗(IMRT)的疗效。方法：采用免疫组织化学检测MGMT阳性表达的Ⅲ～Ⅳ级脑胶质瘤患者34例(包括间变性星形细胞瘤13例，间变性少枝细胞瘤11例，胶质母细胞瘤10例)，分为替莫唑胺联合IMRT同步治疗组(治疗组)15例，单纯IMRT组(对照组)19例。2组均行头颅IMRT 95％计划靶区60 Gy／30f／42 d，治疗组在放疗同时口服替莫唑胺75 mg／m2，每周5 d，共6周，放疗结束后4周再接受4～6疗程化疗，150～200 mg／m2，连服5 d，28 d为一疗程。结果：治疗组客观有效率为46．67％，疾病控制率为86．67％，对照组分别为42．11％和84．21％；中位生存时间治疗组1．5年，对照组1．3年；1年生存率治疗组为60％，对照组为57．89％，2组结果差异均无统计学意义(P0．05)。结论：替莫唑胺联合IMRT同步治疗MGMT阳性的高级别脑胶质瘤的疗效不优于单纯IMRT。
- 脑肿瘤 /
- 适形调强放疗 /
- 替莫唑胺 /
- 6-氧-甲基鸟嘌呤DNA甲基转移酶
Abstract: Objective:To explore the effects of temozolomide(TMZ) combined with intensity-modulated radiotherapy(IMRT) on gliomas with postive O6-methylguanine-DNAmethyltransferase(MGMT). Methods:Thirty-four cases(including 13 cases anaplastic astrocytomas,11 cases anaplastic oligodendrogliomas and 10 cases glioblastomas multiforme) with Ⅲ-Ⅳ grade of MGMT-positive malignant gliomas diagnosed by immunohistochemical method were divided into treatment group(15 cases ) and control group(19 cases). The control group were treated with 95% PTV 60Gy/30f/42d in the head IMRT, and 75 mg/m2 of TMZ was added in the treatment group for 6 weeks(5 days, each week). The treatment group were treated with chemotherapy for 4 to 6 courses within 4 weeks after completing radiotherapy,150-200 mg/m2 was given for 5 days(28 days, each course). Results:The objective effective and disease control rate of the treatment and control group were 46. 67% ＆ 86. 67% and 42. 11% ＆ 84. 21%,respectively. The median survival time of the treatment and control group were 1. 5 and 1. 3 years, respectively. The one-year survival rate of the treatment and control group were 60% and 57. 89%,respectively. There was not statistical significance between two groups(P0. 05). Conclusions: The effects of TMZ combined with IMRT in the treatment of MGMT-positive malignant gliomas are better than that of IMRT alone.
- glioma /
- intensity-modulated radiotherapy /
- temozolomide /
- O6-methylguanine-DNAmethyltransferase

[1]	谷铣之,殷蔚伯,余子豪,等. 肿瘤放射治疗学[M]. 北京:中国协和医科大学联合出版社,2007:1122－1131.
[2] Salcman M,Scholtz H,Kaplan RS,et al. Long-term survival in patients with malignant astrocytoma[J]. Neurosurgery,1994,34(2):213－219.
[3] Hegi ME,Diserens AC,Gorlia T,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med,2005,352(10):997－1003.
[4] Asthagiri AR,Pouratian N,Sherman J,et al. Advances in brain tumor surgery[J]. Neurol Clin,2007,25(4):975－1003.
[5] 印海林,吴伟莉,金风,等. 调强放射治疗联合同步及辅助替莫唑胺化疗治疗脑胶质瘤术后残余病灶的临床研究[J]. 肿瘤,2011,31(5):428－431.
[6] 王若峥,王多明. 调强放疗与替莫唑胺联合治疗颅内恶性胶质瘤 16 例临床分析[J]. 广西医科大学学报,2008,25(5):796－797.
[7] 张海霞,张春霞. 口服抗肿瘤新药替莫唑胺[J]. 国外医学:肿瘤学分册,1999,26(5):292－293.
[8] 李方明,聂青,徐世侠,等. 高度恶性脑胶质瘤放疗联合替莫唑胺(国产) 化疗临床研究[J]. 海军总医院学报,2009,22(1):6－9.
[9] Sun YH,Zhang YZ,Wang HC,et al. Relationship between the expression of O6-methylgunine-DNA methyltransferase in glioma and the survival time of patients[J]. Ai Zheng,2004,23(9):1052－1055.
[10] 杨群英,牟永告,李刚,等. MGMT 表达指导恶性胶质瘤的替莫唑胺化疗:附 40 例报告[J]. 中华神经外科杂志,2011,27(2):112－115.

[1]	徐全敬 , 段诗苗 , 李多杰 . 应用模拟机对头颈肿瘤适形调强放疗进行位置校准探讨. 蚌埠医学院学报, 2012, 36(1): 25-26.
[2]	黄磊 , 程东苗 , 吴迪 , 张正情 , 郭远见 . 食管癌适形调强放疗病人预后多因素回归分析及其预测模型构建. 蚌埠医学院学报, 2022, 47(8): 1030-1033. doi: 10.13898/j.cnki.issn.1000-2200.2022.08.010
[3]	李明 , 廖环 , 李政卫 , 许峰峰 , 肖丽鸿 , 丁强 , 刘信龙 , 徐正平 , 杨冰 . 高压氧治疗对脑膜瘤术后脑水肿及其所致神经功能缺损的实效性评价. 蚌埠医学院学报, 2016, 41(2): 188-190. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.016
[4]	邵华明 , 王穗暖 , 李璐 , 张一 . 乙酰肝素酶和syndecan-1表达与脑胶质瘤恶性程度的关系. 蚌埠医学院学报, 2011, 36(12): 1343-1345.
[5]	李建广 , 张少军 . 岩斜区肿瘤常用手术入路的应用. 蚌埠医学院学报, 2013, 37(2): 237-240.
[6]	张素琴 , 单雪梅 . 经乳突乙状窦前入路切除岩斜区肿瘤患者的护理. 蚌埠医学院学报, 2005, 30(5): 467-468.
[7]	方宪清 , 郑志新 , 程科 . 后颅凹肿瘤手术切除28例体会. 蚌埠医学院学报, 2004, 29(3): 264-265.
[8]	石玉荣 , 章尧 , 甘怀勇 . survivin、caspase-3在脑胶质瘤的表达及suvivin ASODN对U251细胞的影响. 蚌埠医学院学报, 2008, 33(2): 147-149,253.
[9]	马宜传 , 付凯 , 陈岩 , 丁强 , 孙景秋 . 星形细胞瘤脑血容量与RhoA表达相关性研究. 蚌埠医学院学报, 2009, 34(8): 721-723.
[10]	甘怀勇 . 胶质瘤抑癌基因的研究进展. 蚌埠医学院学报, 2005, 30(3): 275-277.
[11]	周莹 , 周胜利 , 刘雨成 . 原发性中枢神经系统淋巴瘤的CT和MRI表现. 蚌埠医学院学报, 2006, 31(1): 72-74.
[12]	包宗玲 , 魏洁 , 项飞 , 丁仁平 . 脑胶质瘤术后放射治疗临床分析. 蚌埠医学院学报, 2006, 31(5): 495-496.
[13]	吴礼高 , 何杰 , 王朝夫 , 吴强 , 龚晓萌 . 胶质瘤p53、p16、bcl-2、c-fos蛋白表达和细胞凋亡. 蚌埠医学院学报, 2006, 31(6): 572-574.
[14]	马宜传 , 付凯 , 孙景秋 . CT灌注成像在脑星形细胞瘤术前分级中的应用. 蚌埠医学院学报, 2009, 34(6): 526-528.
[15]	孙广卫 , 张少军 , 李健 . 脑胶质瘤免疫治疗的进展. 蚌埠医学院学报, 2012, 36(2): 244-247.
[16]	杜维仁 . 原发性脑淋巴瘤的MRI特点. 蚌埠医学院学报, 2007, 32(3): 346-348.
[17]	张应战 , 张禹 , 秦添 , 王星星 , 徐茂林 , 冯雨婷 , 邓雪飞 . 脑多形性黄色星形细胞瘤8例临床、病理、MRI特征及文献复习. 蚌埠医学院学报, 2014, 39(10): 1401-1406.
[18]	杨利辉 , 张颜礼 . 鸦胆子油乳对胶质瘤U251细胞血管内皮生长因子表达水平的影响. 蚌埠医学院学报, 2017, 42(1): 34-35,56. doi: 10.13898/j.cnki.issn.1000-2200.2017.01.009
[19]	赵于飞 , 张红雁 , 吴韦炜 , 吴爱东 , 罗文广 , 程广源 . 调强适形放射治疗鼻咽癌6例体会. 蚌埠医学院学报, 2004, 29(3): 248-250,268.
[20]	赵家成 , 段诗苗 , 李多杰 . 改良体膜在胸部肿瘤适形放疗中的应用. 蚌埠医学院学报, 2012, 36(6): 647-649.

点击查看大图

计量

文章访问数: 3586
HTML全文浏览量: 335
PDF下载量: 126
被引次数: 0

替莫唑胺联合适形调强放射治疗MGMT阳性的高级别脑胶质瘤临床疗效观察

通讯作者: 张红雁;

作者简介: 金雯雯(1983-)，女，住院医师．

1. 1. 安徽省立医院肿瘤放疗科;
2. 2. 安徽省立医院消化内科, 安徽合肥 230001

收稿日期: 2012-02-20
网络出版日期: 2013-01-15

基金项目:

关键词:

摘要: 目的：探讨6-氧-甲基鸟嘌呤DNA甲基转移酶(MGMT)阳性表达的患者应用替莫唑胺联合适形调强放疗(IMRT)的疗效。方法：采用免疫组织化学检测MGMT阳性表达的Ⅲ～Ⅳ级脑胶质瘤患者34例(包括间变性星形细胞瘤13例，间变性少枝细胞瘤11例，胶质母细胞瘤10例)，分为替莫唑胺联合IMRT同步治疗组(治疗组)15例，单纯IMRT组(对照组)19例。2组均行头颅IMRT 95％计划靶区60 Gy／30f／42 d，治疗组在放疗同时口服替莫唑胺75 mg／m2，每周5 d，共6周，放疗结束后4周再接受4～6疗程化疗，150～200 mg／m2，连服5 d，28 d为一疗程。结果：治疗组客观有效率为46．67％，疾病控制率为86．67％，对照组分别为42．11％和84．21％；中位生存时间治疗组1．5年，对照组1．3年；1年生存率治疗组为60％，对照组为57．89％，2组结果差异均无统计学意义(P0．05)。结论：替莫唑胺联合IMRT同步治疗MGMT阳性的高级别脑胶质瘤的疗效不优于单纯IMRT。

English Abstract

The clinical observation of temozolomide combined with intensity-modulated radiotherapy in the treatment of malignant glioma with positive MGMT

Corresponding author: ZHANG Hong-yan

1. 1. Department of Radiotherapy;
2. 2. Department of Digestion, Anhui Provincial Hospital, Hefei Anhui 230001, China

Received Date: 2012-02-20
Available Online: 2013-01-15

Abstract: Objective:To explore the effects of temozolomide(TMZ) combined with intensity-modulated radiotherapy(IMRT) on gliomas with postive O6-methylguanine-DNAmethyltransferase(MGMT). Methods:Thirty-four cases(including 13 cases anaplastic astrocytomas,11 cases anaplastic oligodendrogliomas and 10 cases glioblastomas multiforme) with Ⅲ-Ⅳ grade of MGMT-positive malignant gliomas diagnosed by immunohistochemical method were divided into treatment group(15 cases ) and control group(19 cases). The control group were treated with 95% PTV 60Gy/30f/42d in the head IMRT, and 75 mg/m2 of TMZ was added in the treatment group for 6 weeks(5 days, each week). The treatment group were treated with chemotherapy for 4 to 6 courses within 4 weeks after completing radiotherapy,150-200 mg/m2 was given for 5 days(28 days, each course). Results:The objective effective and disease control rate of the treatment and control group were 46. 67% ＆ 86. 67% and 42. 11% ＆ 84. 21%,respectively. The median survival time of the treatment and control group were 1. 5 and 1. 3 years, respectively. The one-year survival rate of the treatment and control group were 60% and 57. 89%,respectively. There was not statistical significance between two groups(P0. 05). Conclusions: The effects of TMZ combined with IMRT in the treatment of MGMT-positive malignant gliomas are better than that of IMRT alone.